|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS10181|
The increase in research and development funds for drug discovery followed by growing awareness of kidney-related disorders, and diabetes are the major factors driving the expansion of the global diabetic nephropathy market. Globally, many programs are organized by the American Diabetes Association to prevent diabetes, create awareness among vulnerable populations, and ensure that all patients with diabetes are able to get the best care, information and treatment about diabetes management. Thus, the increased awareness about diabetic nephropathy drugs is a new trend that is expected to influence the growth of the global diabetic nephropathy market during the forecast period.
Diabetes is a disease defined by high blood sugar level, caused by inappropriate functioning of the pancreas (the organ which secretes insulin in the body). Nephropathy means kidney impairment or damage. Diabetic nephropathy is the impairment or damage to the kidneys caused by diabetes. It is a disease which affects the kidney glomerulus and one of the most major issues for diabetic patients. Not only the person with diabetes has to undergo kidney impairment, but also the acute cases of diabetic nephropathy could lead to kidney miscarriage. The disease affects the kidneys in a way that makes it futile. Progressive growth in proteinuria and failure in renal function, hypertension, and high risk of cardiovascular disease are the major side effects of chronic diabetic nephropathy. Blood pressure (BP) control is necessary in minimizing the progression of diabetic nephropathy. Irrespective of the agent used, lower blood pressure in type II diabetics could slow down the start and progression of diabetic nephropathy.
On the basis of mode of treatment, the global diabetic nephropathy market is segmented into disease modifying therapies and others. Disease modifying therapies is further categorized into diuretics, angiotensin-converting enzyme inhibitors, antioxidant inflammation modulator, angiotensin receptor blockers, renin inhibitors, calcium channel blockers, connective tissue growth factor inhibitors, monocyte chemoattractant proteins inhibitor, G protein-coupled receptors and endothelin (a receptor antagonist).
There are very few symptoms in the initial stages of diabetic nephropathy; however proteinuria, leg swelling, nocturia, nausea/vomiting and high BP are the common signs and symptoms of advanced diabetic nephropathy. Blood pressure control and glycemic control and are the two major treatments used to limit the development of diabetic nephropathy.
Increasing prevalence of diabetes in various parts of Europe, and the rise in healthcare spending for diabetes treatment are enhancing the growth of European diabetic nephropathy market. Asia-Pacific dominates the global diabetic nephropathy market, owing to an upsurge in diabetic population in several countries such as the Southeast Asian countries and Japan. As per the International Diabetes Federation (IDF), developing countries such as China and India, are anticipated to have maximum number of diabetes mellitus patients, in comparison to developed countries such as Germany and the U.S.
Various government programs are spreading cognizance about diabetes and related renal complications in North America. For example, the National Kidney Disease Education Program (NKDEP) is one of the most important programs organized by the U.S. government, for growing awareness about the various kidney diseases.
Lack of complete therapeutic management for diabetic nephropathy, longer approval time for drugs as well as, harsh regulatory requirements are hampering the market growth of global diabetes nephropathy market.
Some of the major competitors in the global diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie Inc., and Mitsubishi Tanabe Pharma Corporation.